[ad_1] In an analysis of all available data, the FDA found no new or unexpected effects on the safety of pimavanserin (Nuplazid), nor any findings inconsistent with the currently established safety profile …
Read More »FDA analysis concludes no unexpected safety risk associated with pimavanserin
